Systemic lupus erythematosus vaccine - Abraxis BioScience/MedClone

Drug Profile

Systemic lupus erythematosus vaccine - Abraxis BioScience/MedClone

Alternative Names: 3E10 - American Bioscience/MedClone; 3E10 vaccine; Lupus nephritis vaccine - American Bioscience/MedClone; Monoclonal antibody 3E10

Latest Information Update: 28 Aug 2006

Price : $50

At a glance

  • Originator Abraxis BioScience; American BioScience; MedClone
  • Developer American BioScience; MedClone
  • Class Monoclonal antibodies; Vaccines
  • Mechanism of Action Immunostimulants; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 28 Aug 2006 Discontinued - Phase-I for Systemic lupus erythematosus in USA (Intradermal)
  • 28 Aug 2006 Discontinued - Phase-I for Lupus nephritis in USA (Intradermal)
  • 20 Oct 2004 No development reported - Phase-I for Systemic lupus erythematosus in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top